GlassScriptPhysician profile
Ivor Percent
NPI 1619053998
$27,109.96
in general payments reported to CMS, 2019-2025
90 companies · $3,864 in 2025
The $3,864 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,812 · 2020: $1,795 · 2021: $9,139 · 2022: $3,047 · 2023: $3,033 · 2024: $3,420 · 2025: $3,864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,032.78 |
| Education | $284.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $8,148.79 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $1,249.61 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| F. Hoffmann-La Roche Ag | $1,185.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $1,178.50 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,119.18 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Pfizer INC. | $771.53 | 2019-2025 | |
| Janssen Biotech, INC. | $754.95 | 2019-2025 | Tecvayli, Darzalex, Imbruvica |
| Celgene Corporation | $704.68 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Gilead Sciences, INC. | $700.69 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $632.52 | 2021-2025 | Enhertu |
| Incyte Corporation | $612.11 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Astellas Pharma US INC | $549.08 | 2019-2025 | Padcev, Xospata, Xtandi |
| Seagen INC. | $523.45 | 2019-2025 | Padcev, Tukysa, Adcetris |
| Astrazeneca Pharmaceuticals LP | $514.67 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Lilly USA, LLC | $471.49 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
Show all 85 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $466.93 | 2020-2025 | Ojjaara, Shingrix, Zejula |
| Genzyme Corporation | $451.06 | 2019-2025 | |
| Genentech USA, INC. | $428.02 | 2019-2025 | Venclexta, Alecensa, Tecentriq |
| Exelixis INC. | $424.10 | 2020-2025 | Cabometyx |
| Beigene USA, INC. | $343.03 | 2021-2025 | Brukinsa, Tevimbra |
| Takeda Pharmaceuticals U.S.A., INC. | $318.36 | 2023-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Abbvie INC. | $310.96 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $270.67 | 2019-2025 | |
| Boehringer Ingelheim Pharma Gmbh & Co.Kg | $258.28 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $255.00 | 2020-2024 | Libtayo |
| Array Biopharma INC | $253.41 | 2020-2025 | Braftovi, Lorbrena, Mektovi |
| Amgen INC. | $220.68 | 2019-2022 | |
| Eisai INC. | $216.73 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $211.90 | 2020-2025 | |
| Kite Pharma, INC. | $176.06 | 2022-2025 | Yescarta |
| Sobi, INC | $168.77 | 2022-2025 | |
| Puma Biotechnology, INC. | $163.65 | 2019-2025 | |
| Ethicon INC. | $144.76 | 2022 | |
| Beone Medicines USA, INC. | $131.12 | 2025 | Brukinsa, Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $127.71 | 2021-2023 | Imbruvica, Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.43 | 2019-2025 | Gilotrif |
| Kyowa Kirin, INC. | $124.89 | 2022-2025 | Poteligeo |
| Deciphera Pharmaceuticals INC. | $124.01 | 2021-2023 | Qinlock |
| Pharmacosmos Therapeutics INC. | $123.17 | 2023-2025 | Monoferric, Cosela |
| Mirati Therapeutics, INC. | $111.00 | 2023-2024 | Krazati |
| Rigel Pharmaceuticals, INC. | $99.74 | 2020-2024 | Rezlidhia, Tavalisse |
| Karyopharm Therapeutics INC. | $99.56 | 2020-2023 | Xpovio |
| Intuitive Surgical, INC. | $96.31 | 2023 | Da Vinci Surgical System |
| Pharmaessentia USA Corporation | $89.07 | 2022-2024 | Besremi |
| Servier Pharmaceuticals LLC | $83.58 | 2022-2024 | |
| Acrotech Biopharma INC. | $79.69 | 2022-2025 | Beleodaq |
| Stemline Therapeutics INC. | $78.89 | 2023-2024 | Orserdu |
| Sanofi-Aventis U.S. LLC | $75.99 | 2020 | |
| Emd Serono, INC. | $74.80 | 2019-2025 | |
| Myovant Sciences INC. | $72.54 | 2021-2022 | |
| Adc Therapeutics America, INC. | $69.66 | 2022-2024 | |
| Blueprint Medicines Corporation | $66.37 | 2020-2024 | Ayvakit |
| Sumitomo Pharma America, INC. | $63.06 | 2023-2025 | Orgovyx |
| Dova Pharmaceuticals | $61.34 | 2021 | |
| Alnylam Pharmaceuticals INC. | $60.08 | 2023-2024 | Givlaari, Onpattro |
| Dendreon Pharmaceuticals LLC | $58.89 | 2019-2024 | Provenge |
| Aveo Pharmaceuticals, INC. | $56.87 | 2021-2025 | |
| Springworks Therapeutics, INC. | $55.97 | 2024-2025 | Ogsiveo |
| Tersera Therapeutics LLC | $54.65 | 2022 | |
| Genmab U.S., INC. | $50.08 | 2024-2025 | Epkinly |
| Foundation Medicine, INC. | $42.98 | 2020 | |
| Iovance Biotherapeutics, INC. | $42.18 | 2024-2025 | Amtagvi |
| Agios Pharmaceuticals, INC. | $38.52 | 2023-2025 | Pyrukynd |
| Epizyme, INC. | $33.34 | 2022-2024 | Onivyde |
| Alexion Pharmaceuticals, INC. | $31.80 | 2021-2024 | Ultomiris |
| G1 Therapeutics, INC. | $30.60 | 2022-2023 | Cosela |
| Cti Biopharma Corp. | $30.50 | 2023 | Vonjo |
| Legend Biotech USA INC. | $28.38 | 2025 | Carvykti |
| Sirtex Medical INC | $26.47 | 2020 | |
| Telix Pharmaceuticals | $24.56 | 2023 | Illuccix |
| Adaptive Biotechnologies Corporation | $24.08 | 2024 | Clonoseq |
| Sun Pharmaceutical Industries INC. | $24.03 | 2019 | |
| Ge Healthcare | $22.43 | 2022 | |
| Geron Corporation | $22.19 | 2025 | Rytelo |
| Delcath Systems | $20.78 | 2025 | Hepzato Kit |
| Secura Bio, INC. | $20.52 | 2020 | |
| Morphosys, US INC. | $19.86 | 2023 | Monjuvi |
| Cumberland Pharmaceuticals, INC. | $19.21 | 2024 | Sancuso |
| Recordati_rare_diseases_inc. | $17.65 | 2025 | Enjaymo |
| Immunomedics, INC. | $16.28 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $15.92 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $15.60 | 2019 | |
| Horizon Therapeutics Plc | $13.27 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.28 | 2020 | |
| Veracyte, INC. | $1.04 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Keytruda $758Enhertu $642Reblozyl $396Opdivo $378Padcev $363Brukinsa $316Jakafi $312Ojjaara $295Trodelvy $251Elrexfio $218Pluvicto $202Fruzaqla $192Cabometyx $190Verzenio $189Zepzelca $172Tecvayli $164Tukysa $162Jaypirca $160Adcetris $150Imfinzi $148Braftovi $147Lorbrena $144Fabhalta $143Imbruvica $142Darzalex $134Vonjo $132Opdualag $129Lynparza $122Inlyta $120Monjuvi $117Libtayo $114Krazati $111Lenvima $110Ibrance $110Mektovi $108Poteligeo $105Monoferric $103Nubeqa $101Elahere $98.31Da Vinci Surgical System $96.31Xtandi $95.62Yescarta $94.02Venclexta $88.55Tavalisse $87.88Rezlidhia $87.88Epkinly $85.28Promacta $82.19Orserdu $78.89Ninlaro $76.83Bosulif $73.72Calquence $71.33Pomalyst $70.86Carvykti $70.67Scemblix $70.50Rybrevant $69.87Talvey $68.51Beleodaq $65.70Sarclisa $64.46Orgovyx $63.06Tibsovo $63.03Gilotrif $62.40Xospata $62.02Kisqali $60.68Keytruda Qlex $59.52Xalkori $56.01Ogsiveo $55.97Besremi $52.58Stivarga $49.58Vitrakvi $49.58Tecentriq $49.31Alecensa $49.31Rozlytrek $49.31Illuccix $49.12Ziihera $48.49Tevimbra $47.51Polivy $46.90Shingrix $44.66Idhifa $43.46Amtagvi $42.18Bavencio $41.90Nerlynx $41.60Fotivda $40.60Pyrukynd $38.52Lutathera $38.41Givlaari $36.82Cosela $35.80Ayvakit $35.73Gavreto $33.95Avastin $33.95Zejula $33.14Jemperli $33.14Provenge $32.47Doptelet $32.15Lunsumio $31.32Gazyva $31.32Alunbrig $29.44Erleada $26.85Retevmo $24.21Clonoseq $24.08Onpattro $23.26
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivor Percent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.